Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139

Vivani Medical, Inc.

2025-Q2 EPS reported -$0.23 vs consensus -$0.10 ▼ miss (-125.5%)

Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.
Q2 2025 net loss $7.1M vs $5.3M in Q2 2024; cash $8.1M as of June 30, 2025.
Positive preclinical data for NPM-139: ~20% weight loss maintained >6 months with single implant.
Plans to initiate NPM-139 clinical program in 2026; spin off Cortigent division in H2 2025.
Appointed Anthony Baldor as CFO; additional $21.25M committed capital through July 2026.

item 1.01item 2.02item 3.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.